NivolumabPublished on: 12 Apr 2018
Checkpoint inhibitors and platinum as first line treatment for NSCLC
Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.
